Comparison of two different fixed doses of follitropin-β in controlled ovarian hyperstimulation: A prospective randomized, double blind clinical trial

Journal of the Medical Association of Thailand

Volumn 87, Issue 10, 2004, Pages 1151-1155

  Pruksananonda, Kamthorn ^a   Suwajanakorn, Somchai ^a   Sereepapong, Wisan ^a   Virutamasen, Pramuan ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Clinical trial; Follitropin; Infertile; IVF; Oocyte; Ovarian hyper stimulation; Recombinant FSH

Indexed keywords

BUSERELIN ACETATE; CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFICACY; EMBRYO; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OVARY DISEASE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FERTILITY AGENTS, FEMALE; FOLLICLE STIMULATING HORMONE, BETA SUBUNIT; FOLLICLE STIMULATING HORMONE, HUMAN; HUMANS; INFERTILITY, FEMALE; OVULATION INDUCTION; PROSPECTIVE STUDIES;

EID: 8444252165     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Hsueh AJ, Adashi EY, Jones PB, Welsh TH JR. Hormonal regulation of the differentiation of cultured ovarian granulosa cells. Endocr Rev 1984; 5: 76-127.
2. Gemzell CA, Diczfalusy E, Tillinger KG. Human pituitary follicle-stimulating hormone I: clinical effect of a partly purified preparation. Ciba Foren Colloq Endocrinol 1960; 13: 191-200.
3. WHO Agents stimulation gonadal function in human. Report of a WHO scientific group WHO Tech Rep Ser 1973; 514-929.
4. Flamigni C, Venturole S, Dal Prato L, Porcu E. Purified FSH: Characteristics and application. In: Filecole M, Flamigni C, editors. Ovulation induction: Basic science and clinical advances. Elsevier Science 6V: Amsterdam 1994: 125-34.
5. Westergaard LG, Erb K, Laursen S, Rasmussen PE, Rex S. The effect of human menopausal gonadotropin and highly purified, urine derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotropic women. Hum Reprod. 1996; 11: 1209-13.
6. Shoham Z, Insler V. Recombinant technique and gonadotropins production: new era in reproductive medicine. Fertil Steril. 1996; 66: 187-201.
7. Porchet HC, le Cotonnec JY, Loumaye E. Clinical pharmacology of recombinant human follicle-stimulating hormone III. Pharmacokinetic- pharmacodynamic modeling after repeated subcutaneous administration. Fertil Steril. 1994; 61: 687-95.
8. Out HJ, Driessen SG, Mannaerts BM, Coelingh Bennink HJ. Recombinant follicle-stimulating hormone (Follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertil Steril 1997; 68: 138-42.
9. Out HJ, Lindenberg S, Mikkelsen AL, Eldar-Geva T, Healy DL, Leader A. et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon®) in women undergoing ovarian stimulation. Hum Reprod. 1999; 14: 622.
10. Hoomans EH, Andersen AN, Loft A, Leerentveld RA, van Kamp AA, Zech H. A prospective, randomized clinical trial comparing 150 IU recombinant follicle-stimulating hormone(Puregon) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP) in a fixed-dose regimen in women undergoing ovarian stimulatioin. Hum. Reprod. 1999; 14: 2442.
11. Harada T, Yoshida S, Katagiri C, Takao N, Ikenari T, Toda T. et al. Reduced implantation rate associated with a subtle rise in serum progesterone concentration during the follicular phase of cycles stimulated with a combination of a gonadotropin-releasing hormone agonist and gonadotropin. Hum Reprod. 1995; 10: 1060-4.
12. Ubaldi F, Camus M, Smitz J, Bennink HC, Van Steirteghem A, Devrocy P. Premature luteinization in in vitro fertilization cycles using gonatropin-releasing hormone agonist(GnRH-a) and recombinant follicle stimulating hormone(FSH) and GnRH-a and urinary FSH. Fertil Steril. 1996; 66: 275-80.